2.5800
+0.2100
+(8.86%)
At close: April 9 at 4:00:03 PM EDT
2.6500
+0.07
+(2.71%)
After hours: April 9 at 7:59:56 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
57,561
57,561
50,583
47,680
50,832
Cost of Revenue
17,872
17,872
20,831
19,386
14,989
Gross Profit
39,689
39,689
29,752
28,294
35,843
Operating Expense
70,460
70,460
44,854
70,360
70,522
Operating Income
-30,771
-30,771
-15,102
-42,066
-34,679
Net Non Operating Interest Income Expense
-13,380
-13,380
8,859
-12,344
-22,038
Other Income Expense
--
--
-1,382
--
-13,822
Pretax Income
-44,151
-44,151
-7,625
-54,410
-70,539
Tax Provision
-14
-14
245
--
--
Net Income Common Stockholders
-44,137
-44,137
-7,870
-54,410
-70,539
Diluted NI Available to Com Stockholders
-44,137
-44,137
-7,870
-54,410
-70,539
Basic EPS
-0.51
--
-0.13
-1.12
-1.85
Diluted EPS
-0.51
--
-0.13
-1.12
-1.85
Basic Average Shares
86,726.2110
--
61,255.8640
48,734.3770
38,077.6600
Diluted Average Shares
86,726.2110
--
61,255.8640
48,734.3770
38,077.6600
Total Operating Income as Reported
-30,771
-30,771
-15,102
-42,066
-34,679
Total Expenses
88,332
88,332
65,685
89,746
85,511
Net Income from Continuing & Discontinued Operation
-44,137
-44,137
-7,870
-54,410
-70,539
Normalized Income
-44,137
-44,137
-6,778.2200
-54,410
-56,733.5864
Interest Income
3,437
3,437
16,321
99
423
Interest Expense
16,817
16,817
7,462
12,443
22,461
Net Interest Income
-13,380
-13,380
8,859
-12,344
-22,038
EBIT
-27,334
-27,334
-163
-41,967
-48,078
EBITDA
-26,616
-26,616
1,182
-39,580
-45,114
Reconciled Cost of Revenue
17,872
17,872
20,831
19,386
14,989
Reconciled Depreciation
718
718
1,345
2,387
2,964
Net Income from Continuing Operation Net Minority Interest
-44,137
-44,137
-7,870
-54,410
-70,539
Total Unusual Items Excluding Goodwill
--
--
-1,382
--
-13,822
Total Unusual Items
--
--
-1,382
--
-13,822
Normalized EBITDA
-26,616
-26,616
2,564
-39,580
-31,292
Tax Rate for Calcs
0
0
0.0002
0
0
Tax Effect of Unusual Items
--
--
-290.2200
--
-16.5864
12/31/2021 - 7/25/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ETON Eton Pharmaceuticals, Inc.
12.65
+10.29%
AKBA Akebia Therapeutics, Inc.
1.7000
+1.19%
AVDL Avadel Pharmaceuticals plc
7.26
+10.17%
SUPN Supernus Pharmaceuticals, Inc.
31.76
+3.66%
ESPR Esperion Therapeutics, Inc.
1.0500
-0.94%
ASRT Assertio Holdings, Inc.
0.5767
+7.98%
DERM Journey Medical Corporation
6.54
+7.21%
RMTI Rockwell Medical, Inc.
1.1100
+12.12%
BCRX BioCryst Pharmaceuticals, Inc.
6.77
+4.64%
EGRX Eagle Pharmaceuticals, Inc.
1.4000
+21.74%